SPAC13G6.08 Antibody

What is SPAC13G6.08 and why is it important in yeast research?

SPAC13G6.08, also known as Fzr2, is one of the five Fizzy/Cdc20 family members in Schizosaccharomyces pombe, functioning as a putative APC/C (Anaphase-Promoting Complex/Cyclosome) coactivator expressed exclusively during meiosis . Unlike the mitotic coactivators Slp1 and Ste9, Fzr2 belongs to a group of three meiosis-specific coactivators alongside Fzr1/Mfr1 and Fzr3/Mug55 (SPCC1620.04c) . Its importance in research stems from its potential role in the precise orchestration of meiotic progression, though studies of fzr2Δ mutants have shown no significant defects in meiotic progression beyond a slight delay at meiosis completion . Understanding Fzr2 may provide insights into the complex regulatory mechanisms governing meiotic cell division in eukaryotes, particularly those involving APC/C activity modulation.

What applications are recommended for SPAC13G6.08 antibodies?

Based on general antibody application principles and the nature of Fzr2 as a meiosis-specific protein, SPAC13G6.08 antibodies would be most valuable in applications such as Western blotting (WB) and Enzyme-Linked Immunosorbent Assay (ELISA) for detecting protein expression during specific meiotic stages . Immunofluorescence microscopy could be useful for examining the subcellular localization of Fzr2 throughout meiosis. Co-immunoprecipitation experiments would be particularly valuable for investigating potential interactions between Fzr2 and other components of the APC/C complex or with substrates during meiotic progression. When designing experiments, researchers should consider that Fzr2 expression is induced specifically in late meiosis II (approximately 5.5 hours after meiotic induction in synchronized cultures) .

How should SPAC13G6.08 antibodies be stored and handled?

While specific storage conditions for SPAC13G6.08 antibodies are not detailed in the search results, general antibody storage principles should be applied. Based on comparable polyclonal antibodies against S. pombe proteins, researchers should store SPAC13G6.08 antibodies at -20°C or -80°C to maintain stability and activity . Repeated freeze-thaw cycles should be avoided to prevent degradation of the antibody . For working solutions, storage buffers typically contain preservatives such as 0.03% Proclin 300 and stabilizers like 50% glycerol in a pH-controlled environment (such as 0.01M PBS, pH 7.4) . When handling the antibody, researchers should aliquot the stock solution to minimize freeze-thaw cycles and follow strict aseptic techniques to prevent contamination.

How can researchers validate the specificity of SPAC13G6.08 antibodies?

Validating specificity of SPAC13G6.08 antibodies requires multiple complementary approaches. First, researchers should perform Western blots comparing wild-type S. pombe undergoing synchronous meiosis with fzr2Δ deletion mutants. The antibody should detect a band of appropriate molecular weight in wild-type cells specifically during late meiosis II (around 5.5 hours after meiotic induction) but show no signal in the deletion mutant . Additionally, testing the antibody against recombinant SPAC13G6.08 protein would confirm target recognition. Cross-reactivity tests against other APC/C coactivators (particularly the related Fzr1/Mfr1 and Fzr3) are essential to ensure specificity within this protein family. For complete validation, immunoprecipitation followed by mass spectrometry analysis can confirm the identity of the precipitated protein. Peptide competition assays, where the antibody is pre-incubated with excess recombinant SPAC13G6.08 protein before application, should abolish specific signals if the antibody is truly specific.

What controls are essential when working with SPAC13G6.08 antibodies?

When conducting experiments with SPAC13G6.08 antibodies, several controls are essential for result interpretation. For negative controls, researchers should include: (1) fzr2Δ deletion mutant samples to confirm absence of signals, (2) samples from mitotic cells or early meiotic stages when Fzr2 is not expressed, and (3) isotype controls using non-specific IgG of the same species as the primary antibody . Positive controls should include: (1) samples from synchronized cultures at late meiosis II when Fzr2 is known to be expressed (approximately 5.5 hours after meiotic induction) , (2) if available, cells overexpressing tagged Fzr2, and (3) recombinant Fzr2 protein. For loading controls in Western blots, researchers should use antibodies against constitutively expressed proteins such as tubulin or GAPDH. When performing immunofluorescence, inclusion of antibodies against known meiosis II markers will help confirm the developmental stage of the cells being examined.

What expression pattern should researchers expect when detecting SPAC13G6.08?

Based on the available data, researchers should expect a highly specific temporal expression pattern when detecting SPAC13G6.08/Fzr2. In synchronized meiotic cultures using the pat1-114 temperature-sensitive system, Fzr2 protein becomes detectable approximately 5.5 hours after meiotic induction, corresponding to the late stages of meiosis II . The protein is not detectable during mitotic growth or early meiotic stages. This strict temporal regulation makes experimental timing critical when working with Fzr2 antibodies. The following table summarizes the expected expression patterns of APC/C coactivators throughout the meiotic cell cycle in S. pombe:

How can SPAC13G6.08 antibodies contribute to understanding APC/C regulation during meiosis?

SPAC13G6.08 antibodies offer unique opportunities to investigate the specialized regulation of APC/C during meiosis. Researchers can use these antibodies in co-immunoprecipitation experiments to identify meiosis-specific Fzr2-APC/C substrates and compare them with those targeted by other coactivators like Slp1 and Fzr1/Mfr1 . Chromatin immunoprecipitation (ChIP) experiments could reveal whether Fzr2 has any role in regulating gene expression during late meiosis. Importantly, immunoprecipitation studies followed by mass spectrometry can help determine if Fzr2 forms unique APC/C subcomplexes with specific subunits or modifications during meiosis II. The antibodies can also be used to examine how Fzr2 interacts with meiosis-specific APC/C inhibitors like Mes1, which has been shown to interact differentially with Slp1 and Fzr1/Mfr1 . Such studies would provide insights into how cells achieve the precise temporal regulation of APC/C activity needed for proper meiotic progression.

What methodological challenges exist when studying SPAC13G6.08 and how can they be overcome?

Studying SPAC13G6.08/Fzr2 presents several methodological challenges. First, its meiosis-specific expression pattern means that detection is only possible during a narrow time window in late meiosis II . To overcome this, researchers should use highly synchronized meiotic cultures, preferably using the pat1-114 temperature-sensitive system which offers superior synchrony compared to nitrogen starvation methods. Second, functional redundancy between meiotic APC/C coactivators may mask phenotypes in single deletion mutants; indeed, fzr2Δ single mutants and even fzr2Δfzr3Δ double mutants show minimal meiotic defects . This necessitates combinatorial approaches, including creating triple mutants or conditionally depleting multiple coactivators. Third, the protein may be expressed at low levels, requiring sensitive detection methods. Researchers can enhance detection by using signal amplification systems like tyramide signal amplification for immunofluorescence or highly sensitive ECL substrates for Western blots. Additionally, creating strains with tagged versions of Fzr2 under its native promoter can facilitate detection while maintaining physiological expression patterns.

What experimental design is optimal for studying SPAC13G6.08's interactions with other APC/C components?

An optimal experimental design for studying SPAC13G6.08's interactions with APC/C components should incorporate multiple complementary techniques. First, researchers should establish a synchronized meiotic culture system using pat1-114 strains, sampling at regular intervals with particular focus on the 5-7 hour window when Fzr2 is expressed . Co-immunoprecipitation experiments using SPAC13G6.08 antibodies followed by Western blotting for core APC/C subunits can identify which components associate with Fzr2. Reciprocal co-immunoprecipitations using antibodies against APC/C core subunits can confirm these interactions. For detecting transient interactions, researchers should consider crosslinking approaches before immunoprecipitation. Proximity ligation assays or fluorescence resonance energy transfer (FRET) between tagged Fzr2 and APC/C components can provide spatial information about these interactions within intact cells. To understand the functional significance of interactions, in vitro ubiquitination assays using purified components can determine whether Fzr2-APC/C complexes have distinct substrate specificities compared to complexes with other coactivators. Finally, comparing the interactome of Fzr2 with that of Fzr1/Mfr1 and Slp1 using quantitative proteomics would reveal coactivator-specific APC/C configurations or adaptors that might explain their specialized functions during meiosis.

How should researchers interpret SPAC13G6.08 antibody results in the context of meiotic progression studies?

When interpreting SPAC13G6.08 antibody results in meiotic progression studies, researchers should consider several factors. First, the timing of Fzr2 expression is critical - detection should coincide with late meiosis II (approximately 5.5 hours after meiotic induction in synchronized cultures) . Absence of signal before this timepoint reflects normal temporal regulation rather than technical failure. Second, researchers should interpret their results in the context of other meiotic markers and APC/C substrates. For example, correlating Fzr2 detection with the degradation patterns of known APC/C substrates like Cut2/securin and Cdc13/cyclin B can provide insights into its potential function . Third, while fzr2Δ single mutants show minimal phenotypes, this doesn't necessarily indicate lack of function; rather, it may reflect redundancy with other coactivators like Fzr3 . Therefore, antibody-based results showing Fzr2-substrate or Fzr2-APC/C interactions should be considered functionally relevant despite subtle genetic phenotypes. Finally, researchers should compare their Fzr2 findings with data on the better-characterized coactivators Slp1 and Fzr1/Mfr1, which have established roles in anaphase I onset and meiosis II exit, respectively .

How can contradictory results between genetic and antibody-based studies of SPAC13G6.08 be reconciled?

Contradictions between genetic and antibody-based studies of SPAC13G6.08 can often be reconciled through careful analysis of experimental contexts. The most common contradiction might be detecting clear protein expression and interactions via antibodies while observing minimal phenotypes in genetic deletion studies . This can be reconciled by considering functional redundancy - other proteins may compensate for Fzr2's absence in deletion mutants. Researchers should design experiments to test this hypothesis, such as creating double or triple mutants with other meiotic APC/C coactivators, or by acute protein depletion approaches that may reveal phenotypes before compensation mechanisms activate. Another potential contradiction might arise if antibodies detect SPAC13G6.08 outside its expected expression window. This could reflect antibody cross-reactivity with related proteins like Fzr1/Mfr1 or Fzr3, necessitating additional specificity tests. Alternatively, it might reveal genuine but previously undetected expression, which could be confirmed by orthogonal techniques like mass spectrometry or RNA analysis. When faced with contradictions, researchers should also consider strain background differences, synchronization quality, and the sensitivity of phenotypic assays, as subtle defects might be missed by gross morphological analysis but revealed by molecular approaches examining APC/C substrate dynamics.

What are the current knowledge gaps regarding SPAC13G6.08 function and how can antibody studies address them?

Despite the identification of SPAC13G6.08/Fzr2 as a meiosis-specific APC/C coactivator, significant knowledge gaps remain regarding its precise function and regulation. Current research indicates that Fzr2 is induced during late meiosis II, but its deletion causes only minor meiotic delays . This raises questions about its specific substrates, regulatory mechanisms, and potential redundancy with other coactivators. Antibody studies can address these gaps through several approaches. Immunoprecipitation coupled with mass spectrometry can identify Fzr2-specific substrates and interacting proteins that might be distinct from those of Fzr1 or Slp1. Chromatin immunoprecipitation could reveal whether Fzr2 has any unexpected roles in transcriptional regulation during late meiosis. Studies examining post-translational modifications of Fzr2 using modification-specific antibodies might uncover regulatory mechanisms controlling its activity. Additionally, detailed immunolocalization studies could reveal specific subcellular compartments where Fzr2 functions. By comparing cells expressing wild-type Fzr2 versus APC/C-binding mutants using antibody-based approaches, researchers could determine how Fzr2-APC/C interactions influence substrate selection and degradation timing, potentially explaining the precise temporal control of protein degradation required for proper meiotic progression.

How do findings regarding SPAC13G6.08 contribute to our broader understanding of meiotic regulation?

Studies of SPAC13G6.08/Fzr2 contribute significantly to our understanding of meiotic regulation by highlighting the complexity and specialization of APC/C control during gametogenesis. Unlike mitosis, which primarily utilizes two APC/C coactivators (Slp1 and Ste9 in S. pombe), meiosis employs additional specialized coactivators including Fzr2 . This expanded repertoire likely contributes to the precise temporal regulation required for the unique events of meiosis, such as the sequential separation of homologous chromosomes and sister chromatids. The meiosis-specific expression of Fzr2 during late meiosis II suggests evolution has developed specialized mechanisms for controlling late meiotic events . Furthermore, the minimal phenotype of fzr2Δ mutants illustrates the robust nature of meiotic control systems, with built-in redundancy ensuring successful gametogenesis even when individual components are compromised . These findings parallel observations in higher eukaryotes, where tissue-specific APC/C coactivators have been identified in reproductive tissues, suggesting evolutionary conservation of specialized APC/C regulation during gametogenesis across diverse species . Continuing research on SPAC13G6.08 and related proteins will likely reveal additional layers of regulation ensuring the fidelity of meiotic chromosome segregation and cellular differentiation.